Heart Disease News and Research

Latest Heart Disease News and Research

Lotus Pharmaceuticals reports EBIT increase of 29% in 2009

Lotus Pharmaceuticals, Inc., a growing developer, manufacturer and seller of medicine and drugs in the People's Republic of China (the "PRC") reported that its 2009 net earnings were approximately $16.4 million, or $0.33 per diluted share, compared with approximately $12.8 million, or $0.27 per diluted share, in 2008. Net revenues were approximately $57.8 million in 2009 compared with $73.8 million in 2008.

1 Apr 2010

Neogen announces acquisition of GeneSeek

Neogen Corporation announced today that it had purchased all the outstanding shares of GeneSeek, Inc., of Lincoln, Neb. GeneSeek is considered the leading commercial agricultural genetics laboratory in the United States.

1 Apr 2010

ARCA biopharma raises $6.8M through sale of 1,075,000 common stock shares

ARCA biopharma, Inc., a biopharmaceutical company developing genetically targeted therapies for heart failure and other cardiovascular diseases, today announced that during the first quarter of 2010, through its previously established equity distribution agreement, it raised net proceeds of approximately $6.8 million through the sale of 1,075,000 shares of ARCA common stock in open market.

1 Apr 2010

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced that it has signed a co-promotion agreement for Zipsor™ (diclofenac potassium) Liquid Filled Capsules with Ferring Pharmaceuticals Inc., a global bio-pharmaceutical company, headquartered in Switzerland.

1 Apr 2010

Implementation of wait time guarantees: Unfulfilled promises

The Wait Time Alliance (WTA) today expressed disappointment that some jurisdictions have still not fulfilled their 2007 promise to implement wait time guarantees, and other jurisdictions have implemented guarantees that are inconsistent and weak.

1 Apr 2010

Radiology benefit management programs can protect patients from radiation exposure

Making sure patients receive the right diagnostic imaging tests at the right times in high-quality facilities significantly reduces unnecessary radiation exposure, HealthHelp chief medical officer Mark Hiatt, M.D., testified at a public meeting held by the U.S. Food and Drug Administration.

1 Apr 2010

UC Irvine Healthcare's heart failure program earns the Gold Seal of Approval

UC Irvine Healthcare's heart failure program and Stroke & Cerebrovascular Center have again earned the Gold Seal of Approval from The Joint Commission, healthcare's predominant standards-setting and accrediting body.

1 Apr 2010

PolyMedix secures $14M credit facility with Hercules Technology II

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has secured a $14 million credit facility with Hercules Technology II, L.P., an affiliate of Hercules Technology Growth Capital, Inc.

1 Apr 2010

Ensuring medication compliance in clinical trials: Pill capsules with microchips to signal ingestion

Seeking a way to confirm that patients have taken their medication, University of Florida engineering researchers have added a tiny microchip and digestible antenna to a standard pill capsule. The prototype is intended to pave the way for mass-produced pills that, when ingested, automatically alert doctors, loved ones or scientists working with patients in clinical drug trials.

1 Apr 2010

Mount Sinai Medical Center's overall revenue growth for 2009 increased by 5%

Demonstrating the fortitude to address a challenging healthcare environment, president and C.E.O. Steven D. Sonenreich has led Mount Sinai Medical Center to financial stability and successfully reinforced its image as a healthcare leader. The most recent audit posted on March 26 reports nearly $14 million in profit for 2009.

1 Apr 2010

Masimo PVI predicts hemodynamic effects of PEEP in mechanically ventilated patients

Masimo, the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, announced today that a new clinical study published in the March 2010 issue of Anesthesia & Analgesia, shows Masimo PVI successfully predicts the hemodynamic effects of Positive End-Expiratory Pressure in mechanically ventilated patients after cardiac surgery.

1 Apr 2010

New health care reform law includes patient safety provisions

While most of the attention surrounding the landmark health care reform measure just signed into law has focused on how it expands access to affordable insurance coverage, it also enacts important initiatives that will improve patient safety, according to Consumers Union, the nonprofit publisher of Consumer Reports.

1 Apr 2010

FDA accepts for review Abbott's novel diagnostic test for rapid detection of NGAL

A novel diagnostic test to rapidly detect neutrophil gelatinase-associated lipocalin (NGAL), an early biomarker that identifies patients at risk for acute kidney injury (AKI), has been accepted for review by the United States Food and Drug Administration. If approved, this would be the first test available for use in the United States for the detection of NGAL.

1 Apr 2010

Worker health checks reveal 50% men at risk of developing diabetes

Over the last one year 100,000 State Government financed worker health check ups have been conducted. The results have been an eye-opener. 800 workers after their check ups have been asked to consult their physicians immediately. These check ups included measurements of blood pressure, blood cholesterol, blood sugar and waist circumference. The workers were also questioned regarding their eating, drinking and exercising habits.

1 Apr 2010

Cardiac CT can help identify and predict at risk heart attack patients

One of the largest research studies into cardiac computed tomography (CT), conducted at the University of Ottawa Heart Institute (UOHI), shows that the high-speed advanced imaging technology can identify and predict patients at risk for heart attack and death.

1 Apr 2010

Hemosphere completes $9.3M venture capital financing

Hemosphere, Inc., a private medical device company, has completed a late round of venture capital financing totaling $9.3 million. The company has developed the HeRO® Vascular Access Device, which provides access for hemodialysis - the process of filtering waste products from blood when kidneys are in renal failure - similar to a conventional graft.

1 Apr 2010

Orexigen Therapeutics announces submission of Contrave NDA for treatment of obesity

Orexigen® Therapeutics, Inc. announced that the Company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Contrave® (naltrexone SR/bupropion SR), its investigational drug for the treatment of obesity. The NDA is based on a substantial body of evidence gathered through the Contrave Obesity Research (COR) clinical program, which included over 4,500 patients.

1 Apr 2010

Personalized online resource to help Canadians achieve healthy weight loss

A Heart and Stroke Foundation survey of almost 2,000 Canadians found that 62% reported intentionally losing five or more pounds over the past five years but failed to keep the weight off. And 70% of those who were overweight or obese regained all or even more pounds after their weight-loss efforts.

1 Apr 2010

FDA clears AdvanDx' 90 minutes protocol for C. albicans PNA FISH and C. albicans/C. glabrata PNA FISH tests

AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its C. albicans PNA FISH® and C. albicans/C. glabrata PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.

31 Mar 2010

Accellent's net sales for fourth-quarter of 2009 decrease by 12.1%

Accellent Inc., a wholly owned subsidiary of Accellent Holdings Corp., today announced results for its fiscal fourth quarter and full year ended December 31, 2009.

31 Mar 2010